I4V-MC-JAHV - ClinicalTrials.gov - NCT03773978
I4V-MC-JAHV - ClinicalTrials.gov - NCT03773978
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have had a diagnosis of any form of JIA, except systemic JIA, before 16 years of age and JIA must be active
Participants must have had an inadequate response to at least one conventional or biologic disease-modifying anti-rheumatic drug (DMARD)
Participants must NOT
Participants must not have systemic JIA, with or without active systemic features
Participants must not have persistent oligoarticular arthritis
Participants must not have been previously treated with a Janus kinase (JAK) inhibitor
Trial Summary
Conditions the trial is for
Systemic Juvenile Idiopathic Arthritis
What the trial is testing?
Baricitinib, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
197
Trial Dates
December 2018 - March 2022
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have had a diagnosis of any form of JIA, except systemic JIA, before 16 years of age and JIA must be active
Participants must have had an inadequate response to at least one conventional or biologic disease-modifying anti-rheumatic drug (DMARD)
Participants must NOT
Participants must not have systemic JIA, with or without active systemic features
Participants must not have persistent oligoarticular arthritis
Participants must not have been previously treated with a Janus kinase (JAK) inhibitor
Trial Summary
Conditions the trial is for
Systemic Juvenile Idiopathic Arthritis
What the trial is testing?
Baricitinib, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
197
Trial Dates
December 2018 - March 2022
Trial Phase
3
Trial Locations
Hide locations not currently recruiting